Abstract | BACKGROUND: PURPOSE: To compare the benefits and risks of NOACs versus standard thromboprophylaxis for adults having THR or TKR. DATA SOURCES: MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews from January 2009 through March 2013. STUDY SELECTION: English-language systematic reviews. DATA EXTRACTION: Two independent reviewers abstracted data and rated study quality and strength of evidence. DATA SYNTHESIS: LIMITATIONS: Head-to-head comparisons among NOACs were not available. Efficacy is uncertain in routine clinical practice. CONCLUSION: New oral anticoagulants are effective for thromboprophylaxis after THR and TKR. Their clinical benefits over LMWH are marginal and offset by increased risk for major bleeding. PRIMARY FUNDING SOURCE: U.S. Department of Veterans Affairs.
|
Authors | Soheir S Adam, Jennifer R McDuffie, Paul F Lachiewicz, Thomas L Ortel, John W Williams Jr |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 159
Issue 4
Pg. 275-84
(Aug 20 2013)
ISSN: 1539-3704 [Electronic] United States |
PMID | 24026260
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Review, Systematic Review)
|
Chemical References |
- Anticoagulants
- Benzimidazoles
- Factor Xa Inhibitors
- Heparin, Low-Molecular-Weight
- beta-Alanine
- Dabigatran
|
Topics |
- Administration, Oral
- Anticoagulants
(adverse effects, therapeutic use)
- Arthroplasty, Replacement, Hip
(adverse effects)
- Arthroplasty, Replacement, Knee
(adverse effects)
- Benzimidazoles
(adverse effects, therapeutic use)
- Comparative Effectiveness Research
- Dabigatran
- Factor Xa Inhibitors
- Hemorrhage
(chemically induced)
- Heparin, Low-Molecular-Weight
(therapeutic use)
- Humans
- Pulmonary Embolism
(prevention & control)
- Venous Thromboembolism
(prevention & control)
- Venous Thrombosis
(prevention & control)
- beta-Alanine
(adverse effects, analogs & derivatives, therapeutic use)
|